

CURRICULUM VITAE

Galatea Kallergi



PERSONAL INFORMATION

Name: Galatea Kallergi

Nationality: Hellenic

ADDRESS

Home Address: Lefkosias 8, Patra, Greece

Office No: +302610969248

Mobile No: + 30 6944130157

E-mail: gkallergi@upatras.gr, kalergi@med.uoc.gr

EDUCATION

1999-2003 **PhD in Biochemistry**

Laboratory of Biochemistry, School of Medicine, University of Crete, Greece.

Thesis: The dynamic equilibrium of actin cytoskeleton structures in cancer biology.

1995-1997 **MSc in Cell Biology**

Laboratory of Physiology, Department of Biology, University of Crete, Greece.

Thesis: Ontogenesis of the brain: Proliferation and migration of brain cells during embryogenesis in *Coturnix japonica*.

1991-1995 **BSc in Biology**

Laboratory of Physiology, Department of Biology, University of Patras, Greece.

Thesis: Study of Thyroid hormones levels in hyperthyroid and hypothyroid rats after issuing of imidazole.

PROFESSIONAL MEMBERSHIPS

- Associate member of American Association of Cancer Research (AACR)
- Member of the European Liquid Biopsy Society (ELBS)
- Member of Hellenic Society of Biochemistry and Molecular Biology
- Member of HORG (Hellenic Oncology Research Group)

PRINCIPAL INVESTIGATOR IN RESEARCH PROGRAM

- **ESPA 2019: RESEARCH-CREATION-INNOVATION:** Development of innovative diagnostic tools for the detection and characterization of circulating tumor cells (CTCs) in patients' blood.
- **ESPA 2017: RESEARCH-CREATION-INNOVATION:** Hyperspectral Artificial Vision-Guided Robotic Microscope.
- **International collaboration with King Saud University:** The novel oncogene KDM2B in the epigenetic regulation of the cytoskeleton

SENIOR RESEARCHER IN NATIONAL AND INTERNATIONAL RESEARCH PROGRAMMES

1. **BRFAA: EU Research program (2/2018-11/2018)**
A miniature Bio-photonics Companion Diagnostics platform for reliable cancer diagnosis and treatment monitoring
2. **International Clinical Trial, Astra Zeneca (2016-2017).**
Characterization of the molecular changes leading in resistance to 3rd generation EGFR-TKIs in patients with EGFRmut NSCLC using liquid biopsy.
3. **Small Size Research program from Special Research Account University of Crete (2017-2018).**
Evaluation of PD-1 and PD-L1 expression in CTCs isolated from patients with Non-Small Cell Lung Cancer (NSCLC).

- 4. Liquopsy (Principle Investigator) 6/2014-10/2015 Funded by European Regional Development Fund and National Resources (General Secretariat of Research and Technology in Greece)**

In vivo capturing and molecular characterization of circulating tumor cells as a novel tool for improving tertiary prevention in breast cancer.

- 5. Oncoseed (Principle Investigator) (1/3/2012-31/8/2014) (Funded by European Regional Development Fund and National Resources (General Secretariat of Research and Technology in Greece))**

Biology of Circulating Tumour Cells, Distant Metastasis & Development of Liquid Biopsy Methods

- 6. Small Size Research program from Special Research Account University of Crete (2014-2015).**

Effect of chemotherapy on CTCs' phenotype of triple negative (ER-, PR-, HER2-) breast cancer patients

- 7. Small Size Research program from Special Research Account University of Crete (2013-2014).**

Evaluation of Circulating Tumor Cells in Triple negative Breast cancer Patients.

- 8. Small Size Research program from Special Research Account University of Crete (2012-2013).**

Evaluation of EMT phenotype on Circulating Tumor Cells isolated from breast cancer patients.

- 9. Pythagoras I: (Funded by European Regional Development Fund and National Resources (General Secretariat of Research and Technology in Greece) (03/01/2004 to 08/31/2006)**

Actin related signal transduction pathways as a therapeutic target in cancer. (Postdoctoral fellowship)

10. Pilot Study phase 1 administration of Telomerase peptide as immunotherapy in patients with chemoresistant cancer, University of Crete, Greece, (1/11/2011-30/3/2013)

11. Cellular mechanisms of plasticity in neurodegenerative diseases (Funded by European Regional Development Fund and National Resources (General Secretariat of Research and Technology in Greece) (1/1/1998-31/5/1998)

SCHOLARSHIP FOR Msc and PhD THESIS

PhD Scholarship, YPER 1999: (01/01/1999 to 12/31/2001) (Funded by European Regional Development Fund and National Resources (General Secretariat of Research and Technology in Greece)

The dynamic equilibrium of actin cytoskeleton structures in cancer biology.

Msc Scholarships (1/12/1997-31/12/1997) and (1/2/1998-28/2/1998) from Biology Department, University of Crete.

SCIENTIFIC EXPERIENCE

11/2019-Today: **Assistant Professor of Biochemistry**, Department of Biology, University of Patras, Patra, Greece

6/2016-11/2019 **Senior Researcher (Group Leader)** in Department of Biochemistry, School of Medicine, University of Crete, Greece

Research topic: *Identification of signal transduction pathways during metastatic procedure.*

2015: **Visitor scientist** in «The microtubule, signal transduction lab», Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medical College 1300 York Avenue. (Head of the lab Prof. Paraskevi Giannakakou)

2015: **Visitor scientist** in Marlene and Stewart Greenebaum NCI Cancer Center, University of Maryland School of Medicine (Head of the lab Prof. Stuart S. Martin)

2006 –2015 **Senior Researcher** in Laboratory of Tumor Biology, School of Medicine, University of Crete, Greece.

Research topic: *Identification of signal transduction pathways in circulating tumor cells in breast cancer patients.*

Head of the Dep: Prof. Georgoulas Vassilis

2003 – 2006 **Postdoctoral Research Project** in Department of Biochemistry, School of Medicine, University of Crete, Greece.

Title of the project: *Actin related signal transduction pathways as a therapeutic target in cancer.*

Head of the Lab: Prof. Stournaras Christos

1999 – 2003 **Doctoral Research Project** in Department of Biochemistry, School of Medicine, University of Crete, Greece.

Title of the project: *The dynamic equilibrium of actin cytoskeleton structures in cancer biology.*

Head of the Lab: Prof. Stournaras Christos

1997-1999 **Research Project** in Laboratory of Virology, School of Medicine, University of Crete, Greece.

Title of the project: *Study of PTEN onco-suppressor gene in patients with breast cancer.*

Head of the Lab: Prof. Spandidos Dimitris

1995-1997 **MSc Research Project** in Laboratory of Physiology, Department of Biology, University of Crete, Greece.

Title of the project: *Ontogenesis of the brain: Proliferation and migration of cells during embryogenesis in Coturnix japonica.*

Head of the Lab: Prof. Dermon Katerina

1996: **Research in the frames of international collaboration Project** in Laboratory of Ophthalmology in **Tubingen University, Germany.**

Title of the project: *Localisation of GFAP, N2 and Neurofilament in rat retina after destruction of optical nerve and culture in regeneration conditions. Determination of structural changes with electronics microscope.*

Head of the Lab: Prof. Solon Thanos

1995: **Master Rotation** in Institute of Marine Biology of Crete.

Title of the project: *Quantification of NOS positive cells in the brain of red porgy (Pagrus pagrus) and sea bream (Sparus aurata).*

Head of the Lab: Prof. Dermon Katerina

1995: **Master Rotation** in Laboratory of Developmental Biology, Faculty of Medicine, University of Crete

Title of the project: *Immunohistochemical determination of somatostatin in the neural tube of rat embryos*

Head of the Lab: Prof. Karagogeos Domna

1994 - 1995: **BSc Research Project** in Laboratory of Physiology, Department of Biology, University of Patras.

Title of the project: *Study of the levels of thyroid hormones in hypothyroid and hyperthyroid rats after administration of imidazoles.*

In this study the method used was radioimmunoassay (RIA)

Head of the Lab: Prof. Valcana Theoni.

TEACHING EXPERIENCE

2011-2017 Preceptorship in Clinical and Translational Cancer Research.

Seminar for Medical, Surgical or Radiation Oncologists, Pathologists and Basic Scientists at the Department of Medical Oncology and the Laboratory of Cancer Cell Biology, University of Crete Heraklion, Greece

2000-2011 (22 semesters) Scientific Responsible for “**Cell Biology-Morphology**” and “**Genetics**” laboratories & theory in Technological Education Institute of Crete, Greece, Faculty of Crop Science.

2008-2013, 2016 Principles Mechanisms of Oncogenesis, University of Crete Medical School, teaching courses on “Signaling pathways in cancer cells. Growth factors and their receptors”

1996-1997 Teaching courses of “**Physiology**” in laboratory of second cycle students in Department of Biology, University of Crete.

1998-2001 Scientific Responsible of “**Molecular Biology**”, “**Biochemistry I, II**”, “**Biotechnology**”, “**Physiology**” and “**Technology of foods courses**” in Public Institute of professional training of Heraklion

SUPERVISION OF BSc AND PhD –THESIS

2018-2019 Bsc thesis of Spyridoula Ktsarou on: Evaluation of alpha-tubulin, Detyrosinated α -tubulin and Slug in CTCs isolated from NSCLC patients.

- 2016-2018 Bsc thesis of Anastasia Voumvouraki on: Evaluation of new biomarkers Non-Small Cell Lung (NSCLC) Cancer patients.
- 2015-2016 Bsc thesis of Panagiotis Katsarlinos on : Evaluation of the crosstalk between Circulating Tumour Cells (CTCs) and immune cells via PD-1 and PD-L1 pathway in non-small cell lung cancer (NSCLC) patients”
- 2014-2015 BSc Thesis of Valia Tsidari on: CXCR4 pathways in Circulating Tumor Cells.
- 2013-2014 BSc Thesis of Dragolia Melina on: Effect of chemotherapy on CTCs of triple negative (ER⁻, PR⁻, HER2⁻) breast cancer patients.
- 2010-2011 BSc Thesis of Nasias Dimitris on: Expression of p95HER2 receptor in circulating tumor cells of patients with breast cancer.
- 2009-2014 Ph.D Thesis of Maria Papadaki, on: Phenotypic and molecular characterization of micrometastatic cells in patients with breast cancer.
- 2010-2011 BSc Thesis of Mathioudaki Iris on: Phenotypic characterization of micrometastatic cells in patients with triple negative tumors (ER⁻, PR⁻, HER2).
- 2007-2009 BSc thesis of Maria Papadaki on "Investigation of the expression of mesenchymal markers in circulating epithelial tumor cells in patients with breast cancer.

- 2006-2007 BSc thesis of Giannoukaraki Vicky on: Study of VEGF, VEGFR and HIF-1 α in CTCs isolated from breast cancer patients.

PUBLICATIONS IN PEER REVIEW JOURNALS

CITATIONS: 1520 (scopus)

MEAN IF: 5.29

H-INDEX: 20 (scopus),

CORRESPONDING AUTHOR: 12

FIRST/LAST AUTHOR: 17

1. **G. Kallergi**, O. Hoffmann, AK. Bittner, L. Papadimitriou, N Zacharopoulou, M. Zervakis, S. Sfakianakis, C. Stournaras, V. Georgoulas, R. Kimmig, S. Kasimir-Bauer. CXCR4 and JUNB double positive disseminated tumor cells are frequently detected in breast cancer patients at primary diagnosis (Under press in Therapeutic Advances in Medical Oncology)
2. **G. Kallergi**, V. Tsintari, S Sfakianakis, E.S. Bei, N. Zacharopoulou, C. Stournaras, M. Zervakis and V. Georgoulas The prognostic value of JUNB-positive CTCs in metastatic breast cancer; from bioinformatics to immunophenotype. Breast Cancer Res. 2019 Aug 1;21(1):86.
3. A. Kotsakis, **G. Kallergi**, D. Agouraki, Lyristi, Zaharoula, E. Lagoudaki, A. Koutsopoulos, V. Georgoulas E.K. Vetsika., CD8+PD-1+T cells and PD-L-1+ CTCs in chemotherapy naïve NSCLC: Towards their clinical relevance Ther Adv Med Oncol. 2019 Jun 12;11
4. **G. Kallergi**, D. Aggouraki, N. Zacharopoulou, C. Stournaras, V. Georgoulas, S.S. Martin. Evaluation of microtentacles on Circulating Tumor Cells (CTCs); Interaction between CTCs and blood cells through cytoskeletal proteins. Breast Cancer Res. 2018 Jul 5;20(1):67.

5. N. Zacharopoulou, A. Tsapara, **G. Kallergi**, E. Schmid, S. Alkahtani, , S. C. Kampranis, and Ch. Stournaras. The epigenetic factor KDM2B regulates EMT and small GTPases in colon tumor cells. *Cell Physiol Biochem*, 2018 May 14;47(1):368-377
6. **G. Kallergi**, E.K. Vetsika, D. Agouraki, E. Lagoudaki, A. Koutsopoulos, F. Koinis , P. Katsarlinos, M. Trypaki, I. Messaritakis, C. Stournaras, V. Georgoulas, A. Kotsakis. Evaluation of PD-L1/PD-1 on Circulating Tumor Cells (CTCs) in patients with advanced non-small cell lung cancer (NSCLC). *Therapeutic Advances in Medical Oncology Journal*, 2018 Jan 15;10
7. N. Zacharopoulou, A. Tsapara, **G. Kallergi**, E. Schmid, P.N. Tsihchlis, S. C Kampranis & C. Stournaras RhoA/B-GTPases-governed actin cytoskeleton signaling regulates KDM2B-induced motility in prostate cancer cells *Biochim Biophys Acta*. 2018 Apr;1865(4):587-597.
8. E. Politaki, S. Agelaki, S. Apostolaki, D. Hatzidaki, Areti Strati, F. Koinis, M. Perraki, G. Saloustrou, G. Stoupis, **G. Kallergi**, M. Spiliotaki, T. Skaltsi, E. Lianidou, V. Georgoulas, D. Mavroudis: A comparison of three methods for the detection of circulating tumor cells in patients with early and metastatic breast cancer. *Cell Physiol Biochem*, 2017;44(2):594-606.
9. M. J. Stagno, A. Tsapara, N. Zacharopoulou, J. Bochem, L. Pelzl, T. Maghout, **G. Kallergi**, S. Alkahtani, K. Alevizopoulos, K. Dimas, T. Calogeropoulou, S. W. Warmann, F. Lang, E. Schmid, Ch. Stournaras. Istaroxime inhibits motility and down-regulates Orai1 expression, SOCE and FAK phosphorylation in prostate cancer cells. *Cell Physiol Biochem*. 2017 Jul 14;42(4):1366-1376.
10. I. Messaritakis, E. Politaki, A. Kotsakis, K. Dermitzaki, P. Koinis, E. Lagoudaki, A. Koutsopoulos, **G. Kallergi**, J. Souglakos, V. Georgoulas. Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer (SCLC). *PLoS One*. 2017 Jul 18;12(7)

11. M. Spiliotaki, D. Mavroudis, M. Kokotsaki, E. K. Vetsika, I Stoupis, A. Matikas, **G. Kallergi**, V. Georgoulis, S. Agelaki: Insulin-like growth factor-1 receptor expression in circulating tumor cells of patients with breast cancer is associated with E-cadherin expression and patients' outcome (Mol Oncol. 2017 Aug 2doi: 10.1002/1878-0261.12114.)
12. S. Agelaki, Melina Dragolia, H. Markonanolaki, S. Alkahtani, Ch. Stournaras, V. Georgoulis, **G. Kallergi**, Phenotypic characterization of circulating tumor cells (CTCs) in triple negative breast cancer patients (TNBC), Oncotarget 2017 Jan 17;8(3):5309-5322
13. **G. Kallergi**, E. Politaki, S. Alkahtani, C. Stournaras, V. Georgoulis. Evaluation of Isolation methods for Circulating Tumor Cells. Cell Physiol Biochem. 2016;40(3-4):411-419.
14. **G. Kallergi**, S. Agelaki, M. A. Papadaki, D. Nasias, A. Matikas, D. Mavroudis, V. Georgoulis. Expression of truncated HER2 receptor (p95HER2) in Circulating Tumor Cells (CTCs) of breast cancer patients. Breast Cancer Res. 2015 Aug 19;17:113.
15. Agelaki S, Kalykaki A, Markomanolaki H, Papadaki MA, Kallergi G, Hatzidaki D, Kalbakis K, Mavroudis D, Georgoulis. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. PLoS One. 2015 Jun 17;10(6)
16. M Spiliotaki, D Mavroudis, K Kapranou, H Markomanolaki, **G Kallergi**, Filippos Koinis, Kostas Kalbakis, Vassilis Georgoulis, Sofia Agelaki Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. Breast Cancer Res. 2014 Nov 29;16(6):485.
17. ***G Kallergi**, M.A.Papadaki Z Zafeiriou, L Manouras, P.A. Theodoropoulos, D Mavroudis, V Georgoulis, S Agelaki. Co-expression of putative stemness and

- epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. *BMC Cancer*. 2014 Sep 3; 14:651.
18. A Kalykaki, S Agelaki, **G Kallergi**, A Xyrafas, D Mavroudis, V Georgoulas. Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib. *Cancer Chemother Pharmacol*. 2014 Apr;73(4):685-93.
 19. **G Kallergi**, M. Chimonidou, E. Stathopoulos, V. Georgoulas, D. Welch and E. S. Lianidou. Prognostic significance of BRMS1 promoter methylation in operable breast cancer *Mol Cancer Res*. 2013 Oct;11(10):1248-57
 20. ***G. Kallergi**, G. Konstantinidis, H.Markomanolaki, M. A. Papadaki, D. Mavroudis, C. Stournaras, V. Georgoulas, S. Agelaki Apoptotic Circulating Tumor Cells (CTCs) in early and metastatic breast cancer patients *Mol Cancer Ther*. 2013 Sep;12(9):1886-95
 21. V Georgoulas, V Bozionelou, S Agelaki, M Perraki, S Apostolaki, **G Kallergi**, K Kalbakis, A Xyrafas, D Mavroudis. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK19 mRNA-positive circulating tumor cells: results of a randomized phase II study.*Ann Oncol*. 2012 Feb 29.
 22. **G. Kallergi**, M. A. Papadaki, E. Politaki, D. Mavroudis, V. Georgoulas, S. Agelaki, Epithelial-Mesenchymal Transition markers expressed in CTCs of early and metastatic breast cancer patients *Breast Cancer Res*. 2011 10;13(3):R59.
 23. E. Saloustros, M. Perraki, S. Apostolaki, **G. Kallergi**, K. Kalbakis, S. Agelaki, N. Vardakis, A. Kalykaki, A. Xyrafas, V. GeorgoulasD. Mavroudis Cytokeratin-19 mRNA-positive circulating tumor cells during follow up of patients with early breast cancer: prognostic relevance for late relapse. *Breast Cancer Res*. 2011 10;13(3):R60

24. **G. Kallergi**, H Markomanolaki, V. Giannoukaraki, M. A. Papadaki, A. Strati, E. Lianidou, V. Georgoulis D. Mavroudis, S. Agelaki. Hypoxia Inducible Factor 1 alpha (HIF-1 α) and Vascular endothelial growth factor (VEGF) expression in CTCs of breast cancer patients. (2009) Breast Cancer Res 11(6):R84.
25. PA Theodoropoulos, H Polioudaki, S Agelaki, **G Kallergi**, Z Saridaki, D Mavroudis, V Georgoulis. (2009) Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 1;288(1):99-106.
26. S Agelaki., M Spiliotaki , Ch Markomanolaki, **G Kallergi**., D Mavroudis, V Georgoulis. and C. Stournaras (2009). Caveolin-1 regulates EGFR signalling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Cancer Biol Ther. Aug;8(15):1470-7.
27. Papadopoulou N, Papakonstanti EA, **Kallergi G**, Alevizopoulos K, Stournaras C. (2009). Membrane androgen receptor activation in prostate and breast tumor cells: molecular signaling and clinical impact. IUBMB Life, Jan;61(1):56-61. Review.
28. Apostolaki S, Perraki M, **Kallergi G**, Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N, Kalmanti L, Kalbakis K, Agelaki S, Kalykaki A, Stournaras C, Stathopoulos E, Georgoulis V, Mavroudis D. (2008). Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. Breast Cancer Res Treat. Nov 19.
29. **Kallergi G**, Agelaki S., Kalykaki A., Stournaras C., Mavroudis, D. Georgoulis V. (2008) Phosphorylated EGFR and PI-3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients Breast Cancer Res.;10(5):R80.
Highly accessed
30. M Ignatiadis, **G Kallergi**, M Ntoulia, M Perraki, S Apostolaki, M Kafousi, G Chlouverakis, E Stathopoulos, E Lianidou, V Georgoulis, D Mavroudis. (2008)

Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast. *Cancer. Clin Cancer Res.* 14(9):2593-600

31. **G.Kallergi**, S Agelaki, H Markomanolaki, V Georgoulas, C Stournaras.(2007) Activation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells *Cell. Phys. Biochem. Cell Physiol Biochem.* 20(6):977-86.
32. **G.Kallergi**, D Mavroudis, V. Georgoulas and C. Stournaras (2007) Phosphorylation of FAK, PI-3K, and Impaired Actin Organization in CK-positive Micrometastatic Breast Cancer Cells. *Mol. Med.* 13: 79-88
33. **G Kallergi**, A Tsapara, M Kampa, EA Papakonstanti, K Krasagakis, E Castanas, C Stournaras (2003) Distinct signaling pathways regulate differential opioid effects on actin cytoskeleton in malignant MCF7 and nonmalignant MCF12A human breast epithelial cells. *Exp Cell Res.* 288:94-109
34. DA Spandidos, DN Dokianakis, **G Kallergi**, E. Aggelakis (2000) Molecular basis of gynecological cancer *Ann New York Acad Sci.* 900:56-64

AWARDS IN INTERNATIONAL CONFERENCES

- Best project award at **2nd symposium on advances in cancer immunology and immunotherapy 15-17 Dec, Athens 2016.**
- EK Vetsika, **G. Kallergi**, D. Aggouraki, Z. Lyrusti, P. Katsarlinos, F. Koinis, V. Georgoulas, A. Kotsakis. CD8+PD-1+ T cells association with PD-L1+ circulating tumour cells (CTC): An independent prognostic factor in non-small cell lung cancer (NSCLC) patients
- Best Poster Award presented at **9th International Symposium on minimal Residual Cancer, Paris 2013**

M.A Papadaki, **G. Kallergi**, Z. Zafeiriou, V. Georgoulas, P. A. Theodoropoulos, S. Agelaki, D. Mavroudis

Phenotypic characterization of single circulating tumor cells (CTCs) in patients with early and metastatic breast cancer (BC) using stemness and epithelial-to-mesenchymal transition (EMT) markers

•Scholar in Training Grant at 35th **Annual San Antonio USA Breast Cancer Symposium** 2012 (Avon Foundation award)

G. Kallergi, D. Nasias, M. Papadaki, D. Mavroudis, V. Georgoulas, S. Agelaki

Truncated HER2 receptor in Circulating Tumor Cells (CTCs) of early and metastatic breast cancer patients

•Scholar in Training Grant στο 35th **Annual San Antonio USA Breast Cancer Symposium** 2012 (Avon Foundation award)

MA Papadaki, **G. Kallergi**, D. Mavroudis, V. Georgoulas, PA Theodoropoulos, S. Agelaki. Effect of first-line chemotherapy in the expression of stemness and epithelial-to-mesenchymal transition markers in circulating tumor cells of patients with metastatic breast cancer.

•Best Poster Award presented at **International Symposium on Advances in Circulating Tumor Cells (ACTC) Athens 2012**

H. Markomanolaki, **G. Kallergi**, D. Mavroudis,, G. Saloustrou, V. Georgoulas, S. Agelaki. Kinetics of Circulating Tumor Cells (CTCs) in HER2-positive (+) Metastatic Breast Cancer Patients Receiving Trastuzumab.

•Best Poster Award presented at the 7th international symposium on minimal residual cancer, 2009. Athens Greece.

G. Kallergi, H. Markomanolaki, V. Giannoukaraki, M. A. Papadaki, A. Strati, E. Lianidou, V. Georgoulas D. Mavroudis, S. Agelaki.

Angiogenesis associated molecules are expressed in CTCs of breast.

INVITED AND SELECTED ORAL PRESENTATIONS IN NATIONAL AND INTERNATIONAL MEETINGS

- 1. Invited speaker in the 4th ACTC | Advances in Circulating Tumor Cells | Liquid Biopsy: Latest Advances and Future, 2-5 Oct 2019, Corfu, Greece.**

ChallengesThe prognostic value of JUNB-positive CTCs in metastatic breast cancer; from bioinformatics to phenotypic characterization.

- 2. Invited speaker in the 1st Meeting on Liquid Biopsy: Latest developments, opportunities and perspectives in modern oncology, 25th May in Athens.** Phenotypic characterization of CTCs derived from breast and Lung cancer patients.

- 3. Invited speaker in 4th International symposium on advances in cancer immunology and immunotherapy 29 Nov- 1 Dec. Athens, 2018.** Reduction of PD-L1 positive Circulating Tumor Cells (CTCs) in non-small cell lung cancer (NSCLC) patients, treated with Nivolumab

- 4. Invited Speaker in masterclass on Tumor Biomarkers, 20-21 September, Athens 2018:**

- Phenotypic heterogeneity and characterization of CTCs
- Dormancy status of Circulating Tumor Cells in various tumor types

- 5. Invited Speaker in Best of IASLC world conference of Lung Cancer, Athens 23-24 February, Athens 2018:**

a) Characterization of Lung cancer Cell-Free Tumor DNA (cfDNA) shedding and correlation with tumor burden as measured by Recist.

b) Circulating Tumor DNA mutant allele frequency and tumor burden as biomarkers for response to immune checkpoint blockage.

c) 07.06 Innate genetic evolution of lung cancer and spatial heterogeneity: Analysis of treatment-naïve lesions.

d) 07.08 Clinical potential of sputum in detecting driver mutations in patients with non-small cell lung cancer: a preliminary study

6. Invited Speaker in Best of San Antonio Breast Cancer Symposium 20 January, Athens 2018:

- a. Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer.
- b. Genome-wide copy number analysis of chemotherapy-resistant metastatic triple-negative breast cancer from cell-free DNA

7. Oral presentation in 3rd symposium on advances in cancer immunology and immunotherapy 2-4 November, Athens 2017. Evaluation of PD-L1/PD-1 on Circulating Tumor Cells (CTCs) in patients with advanced non-small cell lung cancer (NSCLC)

8. Oral presentation in 3rd ACTC International meeting in 4-7 October. Rhodes 2017. PD-L1 and PD-1 expression in Circulating Tumor Cells (CTCs) isolated from chemotherapy naïve and advanced non-small cell lung cancer (NSCLC) patients.

9. Invited Speaker in “Masterclass on Tumor Biomarkers” 19-20 October Athens 2017: CTCs; Phenotypic heterogeneity and characterization.

10. Oral presentation in 4th Symposium on Thoracic and Upper Aerodigestive Malignancies. 6-9 April, Athens 2017. PD-L1 and PD-1 expression on Circulating Tumor Cells (CTCs) in advanced non-small cell lung cancer (NSCLC) patients treated with Nivolumab.

11. Invited Speaker in “Masterclass in Immunology” 15-17 June, Athens 2017: Circulating Tumor Cells and Immune system.

12. **Oral presentation in 67th Conference of the Hellenic Society for Biochemistry and Molecular Biology 25-27 November Ioannina 2016:** Evaluation of microtentacles on Circulating Tumor Cells (CTCs): Identification of the interaction between CTCs and blood cells through cytoskeletal elements

13. **Invited Speaker in “Masterclass on Tumor Biomarkers” 12-13 May Athens 2016:** CTCs definition and imaging methods for their detection.

14. **Invited Speaker in Best of San Antonio Breast Cancer Symposium – Greece 8-9 January Athens 2016:** a) Nuclear FGFR1 interaction with estrogen receptor (ER) α is associated with resistance to endocrine therapy in ER+/FGFR1-amplified breast cancer. b) ESR1 coregulatory binding inhibitor (ECBI) as a novel therapeutic to target hormone therapy resistant metastatic breast cancer. c) Occurrence of natural ESR1 mutations during acquisition of endocrine resistance in breast cancers and widely used ER+ cell lines.

15. **Invited Speaker in “Masterclass on Tumor Biomarkers” 12-13 Jun 2015:** Phenotypic characterization of CTCs.

16. **Invited Speaker in “Educational Workshop in cancer therapeutics” 3 October 2015, Chania, Greece:** Liquid Biopsy and signal transduction pathways.

17. **Oral presentation in “TEMTIA meeting”, Melbourne 11 October 2015:** Cell Search evaluation of EMT phenotype on CTCs isolated from breast cancer patients.

18. **Invited Speaker in Baltimore, Maryland University, Medical School 23 September 2015:** Identification of metastatic capability of CTCs through microtentacles formation in breast cancer patients- Evaluation of the crosstalk between the cells.

19. **Invited Speaker in Masterclass on circulating Tumor Cells and Molecular Biomarkers: 15-17 Dec 2014:** Circulating Tumor Cells: definitions and imaging methods for detection
20. **Oral presentation Hellenic Society of Medical Oncology annual meeting, Thessaloniki 2014:** Expression of p95HER2 receptor in CTCs isolated from 1st line breast cancer patients.
21. **Invited speaker in Educational symposium in clinical oncology, November 2012, Heraklion, Crete, Greece:** Phenotypic characterization of CTCs isolated from patients with Triple negative (ER-, PR-, HER2-) tumors.
22. **Oral presentation Hellenic Society of Medical Oncology annual meeting, April, Athens 2012:** Evaluation of apoptosis on CTCs of early and metastatic breast cancer patients.
23. **Oral presentation in International Symposium on Advances in Circulating Tumor Cells (ACTC) 29 September Athens, 2012:** Apoptosis and proliferation in CTCs of early and metastatic breast cancer patients.
24. **Invited speaker in Educational symposium in clinical oncology, November 2010, Heraklion, Crete, Greece:** Evaluation of apoptosis on CTCs
25. **Oral presentation Hellenic Society of Medical Oncology annual meeting, Athens 2008 :** Activation of EGFR and PI-3 Kinase in CTCs
26. **Invited speaker in Educational symposium in clinical oncology, November 2007, Heraklion, Crete, Greece:** Phosphorylation of EGFR and the signal transduction molecules in CTCs of breast cancer patients.

27. **Invited speaker in Educational symposium in clinical oncology, November 2005, Heraklion, Crete, Greece:** Signal transduction pathways on CTCs

28. **Invited speaker in Educational symposium in clinical oncology, November 2004, Heraklion, Crete, Greece:** Expression of Focal Adhesion Kinase in CTCs.

ORGANIZATION OF SCIENTIFIC WORKSHOP

Scientific organizer of workshop: DETECTION METHODS OF CTCs

12 OCTOBER 2014, HERAKLION, CRETE, GREECE

ANNOUNCEMENTS IN NATIONAL AND INTERNATIONAL MEETINGS

1. S. D. Katsarou, A. Voumvouraki, C. Stouraras, S. S. Martin, V. Georgoulis **G. Kallergi**. The prognostic value of alpha tubulin overexpression in CTCs isolated from Non-Small Cell Lung Cancer (NSCLC). 4th ACTC | Advances in Circulating Tumor Cells | Liquid Biopsy: Latest Advances and Future, 2-5 Oct 2019, Corfu, Greece.
2. **G. Kallergi**, O. Hoffmann, AK. Bittner, L. Papadimitriou, S. D. Katsarou, N. Zacharopoulou, M. Zervakis, S. Sfakianakis, C, Stournaras, V. Georgoulis, R. Kimmig, S. Kasimir-Bauer. CXCR4 and JUNB double positive Disseminated Tumor Cells are frequently detected in breast cancer patients at primary diagnosis. 4th ACTC | Advances in Circulating Tumor Cells | Liquid Biopsy: Latest Advances
3. **G. Kallergi**, A. Voumvouraki, N. Zacharopoulou¹, C. Stournaras¹, S. S. Martin, V. Georgoulis. Alpha-tubulin and detyrosinated α -tubulin in CTCs derived from non-small cell lung cancer (NSCLC) patients. International Symposium on Minimal Residual Cancer (ISMRC), 3-5 May, Montpellier, France

4. **G. Kallergi**, A. Koutsopoulos, E. Lagoudaki, D. Agouraki, E.K. Vetsika, Stuart S. Martin, A. Voumvouraki, F. Koinis, C. Stournaras, V. Georgoulas, A. Kotsakis. Detection of PD-L1 and PD-1 positive circulating tumor cells (CTCs) in non-small cell lung cancer (NSCLC) patients treated with nivolumab. **AACR Annual Meeting 14-18 April, Chicago, USA, 2018.**

5. **G. Kallergi**, O. Hoffmann, N. Zacharopoulou, Ch. Stournaras, V. Georgoulas, S. Kasmir-Bauer. Overexpression of CXCR4 and JUNB in Disseminated Tumor Cells (DTCs) isolated from breast cancer patients before neoadjuvant treatment. **Cancer Research 78 (13 Supplement), 5186-5186, AACR Annual Meeting 14-18 April, Chicago, USA, 2018.**

6. **Kallergi**, G. Galetti, T. E. McGraw, D.M. Tsiridou, C. Stournaras, V. Georgoulas, N. Altorki, P. Giannakakou. Overexpression of Transferrin receptor 1 (TFR) in CTCs is a poor prognostic factor for breast cancer patients. **ACTC International meeting, Rhodos, 4-7 October, Greece, 2017.**

7. **G. Kallergi**, S. S. Martin, D. Agouraki, C. Stournaras, V. Georgoulas. Evaluation of Microtentacles on Circulating Tumor Cells (CTCs); Interaction between CTCs and Blood cells through cytoskeletal proteins. **ACTC International meeting, Rhodos 4-7 October, Greece, 2017.**

8. A. Ntzifa, **G. Kallergi**, N. Karachaliou, Ch. Charalambous, N. Kentepozidis, M. Nikolaou, I. Boukovinas, E. Lianidou, V. Georgoulas, A. Kotsakis. Preliminary results of phenotypic characterization of Circulating Tumor Cells and monitoring of EGFR mutations using liquid biopsy in patients with EGFRmut NSCLC treated with AZD9291. **ACTC International meeting, Rhodos 4-7 October, Greece, 2017.**

9. E-K Vetsika, D. Agouraki, **G Kallergi**, Z. Lyritzi, A. Koukos, D. Kourougkiaouri, K. Rounis, V. Georgoulas, A. Kotsakis. Correlation of immune

and Circulating Tumor Cells in respect to PD-1 and PD-L1 expression during treatment in NSCLC patients. **ACTC International meeting, Rhodes 4-7 October, Greece, 2017.**

10. **G. Kallergi**, E.K. Vetsika, D. Aggouraki, E. Lagoudaki, A. Koutsopoulos, F. Koinis, P. Katsarlinos, M. Trypaki, C. Stournaras, V. Georgoulas, A. Kotsakis. Evaluation of PD-L1/PD-1 on circulating tumor cells (CTCs) and on primary tumor in advanced non-small cell lung cancer (NSCLC). . **Cancer Research July 2017 Vol 77, Issue 13 Suppl. AACR Annual meeting, 1-5 April, Washington DC, USA, 2017.**
11. E.K. Vetsika, **G. Kallergi**, D. Aggouraki, Z. Lyristi, A. Koukos, D. Kourougkiaouri, F. Koinis, V. Georgoulas, A. Kotsakis. Effect of anti-PD-1 therapy on immune cells in the peripheral blood of non-small cell lung cancer patients. **Cancer Research, July 2017 Vol 77, Issue 13 Suppl. AACR Annual meeting, 1-5 April, Washington DC, USA, 2017.**
12. G. Galletti, **G. Kallergi**, A. Saxena, D. Aggouraki, C. Stournaras, V. Georgoulas, T. E. McGraw, N. Altorki, P. Giannakakou. Transferrin receptor 1 (TfR) as marker for circulating tumor cells (CTCs) identification in NSCLC. **Cancer Research, July 2017 Vol 77, Issue 13 Suppl. AACR Annual meeting, 1-5 April, Washington DC, USA, 2017.**
13. E. Saloustros, H. Latsoudis, D. Vassou, **G. Kallergi**, I. Stratidaki, N.-A. Gounalaki, I. Drositis H. Latsoudis. The pursue of genetic mechanisms underlying supreme response to pazopanib treatment. **Cancer Research Vol 77, Issue 13 Suppl. AACR Annual meeting, 1-5 April, Washington DC, USA, 2017.**
14. **G. Kallergi**, D. Agouraki, P. Katsarlinos, E.K. Vetsika, E. Lagoudaki, F. Koinis, A. Koutsopoulos, V. Georgoulas, A. Kotsakis. Evaluation of PD-1 and PD-L1 expression on CTCs isolated from non-small cell lung cancer (NSCLC) tumor patients. **ESMO Congress 2016, 7-11 October, Copenhagen, Denmark 2016.**

15. **G. Kallergi**, S. S. Martin, P. Katsarlinos, V. Georgoulas
16. Evaluation of a tubulin, detyrosinated tubulin and vimentin expression in CTCs; Identification of the interaction between CTCs and blood cells through cytoskeletal elements. **Cancer Research, Vol 76 Issue 14 Suppl. AACR annual meeting, April 16 – 21, New Orleans, USA, 2016.**
17. A.Strati, Martha Zavridou, **Galatea Kallergi**, Eleni Politaki, Tobias Gorges, Andra Kuske, Anna-Lena Bohnen, George Koutsodontis, Amanda Psyrrri, Klaus Lucke, Vasilis Georgoulas, Klaus Pantel, Evi Lianidou Molecular characterization of in vivo isolated EpCAM-positive circulating tumor cells in breast cancer. **Cancer Research Vol 76, issue 14 Suppl. July 2016. AACR annual meeting, April 16 – 21, New Orleans, USA, 2016.**
18. E-K Vetsika, **G Kallergi**, Despoina Aggouraki, Z Lyristi, P Katsarlinos, Filippos Koinis, V Georgoulas, Athanasios Kotsakis. High frequencies of PD-1+CD8+ T cells are correlated with PD-L1+ circulating tumor cells (CTC) and have predictive/prognostic value in non-small cell lung cancer (NSCLC) patients, **Journal for Immunotherapy of Cancer 2016, Vol 4 Suppl. 31st Annual Meeting and Associated. Programs of the Society for Immunotherapy of Cancer (SITC 2016): National Harbor, MD, USA. 9-13 November 2016**
19. Markomanolaki, H.; Mavroudis, D.; **Kallergi, G.**; et al., HER2 expression on circulating tumor cells before adjuvant chemotherapy and during follow-up in patients with HER2-negative early breast cancer **Cancer Research, Volume: 76, Vol 4 Suppl. Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12; San Antonio, TX, 2015.**
20. **G. Kallergi**, Eleni Politaki, Stella Apostolaki, Sophie Laget, Vassilis Georgoulas: Evaluation of Isolation methods for Circulating Tumor Cells. **10th ISMRC International Symposium on Minimal Residual Cancer: Liquid Biopsy in Cancer Diagnostics and Treatment March 19-21 in Hamburg, Germany 2016.**

21. **Kallergi, G**, Politaki, E, Georgoulas, V: EMT phenotype on CTCs isolated from early and metastatic breast cancer patients. **10th ISMRC International Symposium on Minimal Residual Cancer: Liquid Biopsy in Cancer Diagnostics and Treatment March 19-21 in Hamburg, Germany, 2016.**
22. **G. Kallergi**, V. Tsintari, S Sfakianakis, M. Zervakis, D. Mavroudis, V. Georgoulas: CXCR4 pathways in CTCs: From bioinformatics to immunophenotype. **Cancer Research, Volume: 75, Vol 15 Suppl. 2015. AACR annual meeting, April 18 – 22, Philadelphia, USA, 2015.**
23. **Kallergi G**, Dragolia M, Mavroudis D, Georgoulas V, Agelaki S.: Effect of adjuvant chemotherapy on the phenotype of circulating tumor cells in patients with triple negative breast cancer. **Cancer Research Volume: 74 Issue: 19 Suppl. AACR annual meeting, April 5 - 9, San Diego, USA, 2014.**
24. Aggouraki D; Papadaki M; Vetsika EK; et al Correlation of circulating tumor cells (CTCs) expressing stemness and EMT phenotypes with immunosuppressive cells in metastatic breast cancer patients **Cancer Research Volume: 74, Issue: 19, Suppl. AACR annual meeting, April 5 - 9, San Diego, USA 2014.**
25. **G. Kallergi**, M. Papadaki, D. Mavroudis, V. Georgoulas, S. Agelaki. Identification of truncated HER2 receptor on Circulating Tumor Cells (CTCs), before and after Trastuzumab treatment in metastatic breast cancer patients. **9th International Symposium on minimal Residual Cancer in Paris, France 2013.**
26. **Kallergi G** , Markomanolaki, Mavroudis, Georgoulas V, Agelaki S Phenotypic characterization of circulating tumor cells (CTCs) in triple negative breast cancer patients., **Cancer Research, Volume: 73, Issue 24 Suppl. Annual meeting of AACR, Washington DC, USA, 2013.**
27. Agelaki, S.; Mavroudis, D.; Politaki, E. et al. Prognostic value of CTC detection by RT-PCR and the CellSearch system before first-line chemotherapy in

metastatic breast cancer. **Cancer Research Vol: 73 Issue 24 Suppl. Annual meeting of AACR, Washington DC, USA, 2013.**

28. Papadaki, M. A.; Agelaki, S.; Kallergi, G.; et al. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer **Cancer Research Vol: 73 Issue 24 Suppl. Annual meeting of AACR, Washington DC, USA, 2013.**
29. Soiliotaki, M, Markomanolaki, H, **Kallergi, G.** et al. Evaluation of proliferation and apoptosis markers in circulating tumor cells (CTCs) of women with early breast cancer who are candidates for tumor dormancy. **European J. of Cancer Volume: 49 Issue 2 Suppl. Pages: S434-S434. Markers in Cancer: A joint meeting by ASCO, EORTC and NCI, Brussels, Belgium, 2013.**
30. Agelaki, S., Kalykaki A., Markomanolaki, H, **Kallergi G.** et al. A pilot feasibility study to evaluate the efficacy of lapatinib in eliminating HER2-positive tumor cells circulating in peripheral blood of women with metastatic breast cancer. **Journal. of Clin. Oncology Volume: 31 Issue 15 Suppl. ASCO Meeting, Chicago, IL May 31-June 4, 2013.**
31. Spiliotaki M, Markomanolaki H, **Kallergi, G.** et al. Evaluation of proliferation and apoptosis markers in circulating tumor cells (CTCs) of women with early breast cancer who are candidates for tumor dormancy. **Journal. of Clin. Oncology Volume: 31 Issue 15 Suppl. MAY 20 2013, ASCO Meeting, Chicago, IL May 31-June 4, 2013**
32. Chimonidou, M. **Kallergi, G,** Georgoulas, V. et al. Prognostic significance of BRMS1 promoter methylation in operable breast cancer. **Cancer Research, Volume: 73, Issue 8 Suppl. AACR Annual Meeting 2013; Apr 6-10, 2013; Washington, DC.**

33. **G. Kallergi**, D. Nasias, M. Papadaki, D. Mavroudis, V. Georgoulas, S. Agelaki. Truncated HER2 receptor in Circulating Tumor Cells (CTCs) of early and metastatic breast cancer patients. **Cancer Research, Volume: 72 Issue 24 Suppl. 2012. 35th Annual San Antonio USA Breast Cancer Symposium 2012**
34. Papadaki, M. A. **Kallergi, G.** Mavroudis, D. et al. Effect of first-line chemotherapy in the expression of stemness and epithelial-to-mesenchymal transition markers in circulating tumor cells of patients with metastatic breast cancer. **Cancer Research Volume 72 Issue 24, Suppl. 2012 35th Annual San Antonio USA Breast Cancer Symposium 2012**
35. . **G Kallergi**, N. Dimitris, M. Papadaki, D. Mavroudis, V. Georgoulas S. Agelaki. Expression of truncated HER2 receptor in Circulating Tumor Cells (CTCs) of breast cancer patients. **Cancer Research, Volume 72, Issue 8 Suppl., 2012. 103rd Annual meeting of AACR, Chicago, USA, 31 March-4 April 2012**
36. Papadaki, M, **Kallergi, G**, Agelaki, S, et al. Analysis of the expression of stemness and epithelial-to-mesenchymal transition markers in circulating tumor cells of patients with breast cancer **Cancer Research, Volume 72, Issue 8 Suppl., 2012. 103rd Annual meeting of AACR, Chicago, USA, 31 March-4 April 2012.**
37. **G. Kallergi**, G. Konstantinidis, M. Papadaki, S. Agelaki, D. Mavroudis, Ch. Stournaras, V. Georgoulas. Apoptotic Circulating Tumor Cells (CTCs) in early and metastatic breast cancer patients. **Cancer Research, Volume: 71, Issue 8, Suppl. 2011. 102nd Annual meeting of AACR, Orlando, Florida, USA, 2-6 April 2011.**
38. **G. Kallergi**, S. Agelaki, A. Mathioudaki, D. Mavroudis, V. Georgoulas. Phenotypic characterization of circulating tumor cells (CTCs) in triple negative breast cancer patients. **EJC SUPPLEMENTS Volume 8, Issue: 7. 22nd EORTC - NCI - AACR Symposium on Molecular Targets and Cancer Therapeutics, Berlin, Germany, 16 - 19 November 2010.**

39. Georgoulas, V.; Bozionelou, V.; Agelaki, S.; et al. Trastuzumab versus observation in women with early breast cancer and CK-19 mRNA-positive circulating tumor cells (CTCs): A pilot randomized phase II study. **J. of Clin. Oncology, Volume: 28 Issue 15 Suppl. ASCO annual meeting May 2010.**
40. **G. Kallergi**, M.A. Papadaki, S. Agelaki, D. Mavroudis, V. Georgoulas Distinct expression of Twist and Vimentin in CTCs of early and metastatic breast cancer patients **7th international symposium on minimal residual cancer, Athens Greece, 2009.**
41. **G. Kallergi**, M. A. Papadaki, S. Agelaki, D.Mavroudis, V.Georgoulas Epithelial-Mesenchymal Transition markers are expressed in CTCs of breast cancer patients. **Ann of Oncol., Vol 20: 56-56. IMPAKT Breast Cancer Conference Brussels, Belgium 2009.**
42. **G. Kallergi**, H. Markomanolaki¹, V. Giannoukarak¹, M. A. Papadaki¹, A. Strati², E. Lianidou², V. Georgoulas^{1,3} D. Mavroudis^{1,3}, S. Agelaki^{1,3} Angiogenesis associated molecules are expressed in CTCs of breast cancer patients. **7th international symposium on minimal residual cancer, Athens 2009.**
43. **G. Kallergi**, S.Agelaki, V. Giannoukarak¹, H. Markomanolaki, E. Lianidou, D. Mavroudis, V. Georgoulas. VEGF, VEGFR2 and HIF-1 α expression in Circulating Tumor Cells (CTCs) of breast cancer patients. **Cancer Research. Vol 69: 114S-114S. 31st Annual San Antonio USA Breast Cancer Symposium 2008**
44. **G. Kallergi**, S.Agelaki, V. Giannoukarak¹, H. Markomanolaki, E. Lianidou, D. Mavroudis, V. Georgoulas Vascular endothelial growth factor (VEGF)

expression in CTCs of breast cancer patients. **99th annual meeting of AACR, San Diego, USA 2008.**

- 45. G. Kallergi, S. Agelaki, V. Georgoulas and Ch. Stournaras.** Activation of FAK/PI3K/Rac1 signaling pathway in A375 melanoma cells. **1st Hellenic symposium in Research Dermatology, Heraklion October, Greece 2008**
46. Ignatiadis M, **Kallergi G**, Ntoulia M, Apostolaki S, Perraki M, Xenidis N, Stathopoulou A, Lianidou E, Georgoulas V, Mavroudis D. Prognostic value of the detection of Circulating Tumor Cells using a multimarker RT-PCR (CK19, mammaglobin A, HER2/neu) in early breast cancer **Breast Cancer Res. Treat. Vol 106: S26-S26. 30th Annual San Antonio USA Breast Cancer Symposium 2007.**
47. **G Kallergi**, A Kalykaki, S Agelaki, D Mavroudis, V Georgoulas. EGFR, pAkt and pPI-3 kinase are co-expressed in circulating tumor cells of breast cancer patients. **Breast Cancer Res. Treat Vol. 106: 245-S245. 30th Annual San Antonio USA Breast Cancer Symposium 2007.**
- 48. S. Agelaki, M. Spiliotaki, C. Markomanolaki, G. Kallergi et al. (2007)** Caveolin-1 enhances the growth inhibitory effects of gefitinib in MCF-7 breast cancer cell line. **Breast Cancer Res. Treat. Vol 106: S162-S163. 30th Annual San Antonio USA Breast Cancer Symposium 2007.**
49. **G. Kallergi** , S. Agelaki , A. Kalykaki , D. Mavroudis , V. Georgoulas. EGFR, pAkt and pPI-3 kinase are co-expressed in circulating tumor cells (CTCs) of patients (pts) with breast cancer. **6th international symposium on minimal residual cancer, Hamburg Germany 2007.**
50. **G. Kallergi**, V. Minas, D. Mavroudis, A. Gravanis, V. Georgoulas and C. Stournaras. Analysis of pro-survival mechanisms in circulating tumor cells. **6th**

international symposium on minimal residual cancer, Hamburg Germany 2007.

51. **G. Kallergi**, D. Mavroudis, V. Georgoulas and C. Stournaras Regulation of migration and survival mechanisms in circulating micrometastatic tumor cells. **Febs J. 274: 175-175. 32nd FEBS Congress Vienna, Austria, 2007.**
52. **G. Kallergi**, S. Agelaki, A. Kalykaki, M. Spiliotaki, M. Perraki, D. Mavroudis, V. Georgoulas. EGFR, pAkt and pPI-3 kinase are co-expressed in circulating tumor cells of breast cancer patients. **Cancer Research Vol 67, Issue 9 Suppl. 98th Annual meeting of AACR, Los Angeles, USA, 2007.**
53. **G. Kallergi**, D. Mavroudis, A. Gravanis, V. Georgoulas and C. Stournaras PI-3 kinase, FAK and Akt are constitutively active in occult tumor cells of breast cancer patients. **XX th FECTS Meeting, Oulu, Finland, 2006**
54. **G. Kallergi**, D. Mavroudis, V. Georgoulas and C. Stournaras
 - a. Regulatory role of FAK / PI-3K / actin signalling in cancer cells **31st FEBS Congress Istanbul, Turkey, 2006.**
55. **G. Kallergi**, Ch. Mavroudi, E. Politaki, D. Mavroudis, V. Georgoulas and C. Stournaras Cytokeratin-positive micrometastatic human breast cancer cells express Her2 and phosphorylated FAK and PI-3 kinase. **Cancer Research Vol 66, Issue 8 Suppl. 97th annual meeting of AACR, Washington, USA, 2006.**
56. **G. Kallergi**, D. Mavroudis, A. Gravanis, V. Georgoulas and C. Stournaras. FAK and PI-3K are activated in micrometastatic human breast cancer cells. **Febs J. Vol 272: 314-314. 30th FEBS Congress - 9th IUBMB Conference, Budapest, Hungary, 2005.**
57. **G. Kallergi**, K. Krasagakis, A.D. Tosca, C. Stournaras. Selective effects of opioids in actin cytoskeleton of human breast cancer cells **XVII FECTS meeting Patras, Greece, 2000.**

58. C.R. Derrmon, A. Stamatakis, **G. Kallergi**, L. Panagis. Developmental pattern of NADPH-diaphorase in chick mesencephalon - Diencephalon. **Eur. J. Neuroscience. 10: 282-282. Forum of European Neuroscience Berlin, Germany, 1998.**
59. **Kallergi G**, Stamatakis A, Barbas H, Dermon K. Ontogeny of proliferative cells during late embryonic brain histogenesis of Japanese Quail. **Annual meeting of Society for Neuroscience 27th New Orleans, USA, 1997**

REVIEWER IN PEER REVIEW JOURNALS

- Annals of Oncology
- Cancer Research
- Oncotarget
- Scientific reports
- BMC cancer
- Medical Principles & Practice
- Molecular Cancer
- Cellular Physiology & Biochemistry
- PLOS one etc
- Molecular Cancer

COMPUTATIONAL AND OTHER SKILLS

- Grant writing Course (AACR Annual Meeting 2016, New Orleans, LA)
- Windows and Macintosh platform user
- Apt user of Microsoft Office programs
- Apt user of Image analysis programs (ARIOL system , Confocal laser Scanning etc)
- SPSS seminar 2012, Athens
- Best clinical practice seminar (Roch&HORG) Athens 2016

LANGUAGES

- Greek: native speaker
- English: Proficiency level
- French: Basic level

NATIONAL AND INTERNATIONAL COLLABORATIONS

Evi Lianidou: Professor of Analytical Chemistry, University of Athens, Greece

Michael E. Zervakis: Professor, School of Electronic and Computer Engineering, Technical University of Crete, Greece

Costas Balas: Professor, Director of the Electronics, Technical University of Crete, Chania, Greece.

Stuart S. Martin, Associate Professor of Physiology, Marlene and Stewart Greenebaum NCI Cancer Center, University of Maryland School of Medicine

Paraskevi (Evi) Giannakakou, Professor of Pharmacology in Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medical College 1300 York Avenue

Kasimir-Bauer, Sabine, Professor Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Germany.

